Compare Citius Pharmaceuticals Inc (CTXR) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NetApp Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while NetApp Inc. trades at $200.5 (market cap $38.95B). The key difference: NetApp Inc. is far larger — about 1946.5× Citius Pharmaceuticals Inc's market cap, and NetApp Inc. pays a 1.05% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NTAP | |
|---|---|---|
Market Cap | $20.01M | $38.95B |
Sector | Health | Technology |
52-Week High | $1.82 | $198.72 |
52-Week Low | $0.48 | $94.11 |
Enterprise Value | $16.23M | $38.10B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
NetApp (NTAP) trades at $200.96, up 1.13% with strong technical momentum as it approaches resistance near $201. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.43 vs. $2.27 expected) and impressive profitability metrics including 70.74% gross margin and 106.73% ROE. Recent acquisitions of JetStream Software and DataPelago strengthen the company's AI infrastructure capabilities, positioning it for growth in the enterprise data storage market.
Outlook remains positive with Wall Street analysts maintaining a mixed but leaning bullish stance (36.62% Buy ratings). Key opportunities include AI-driven demand for data infrastructure, while risks involve elevated valuation multiples (P/E 31.26) and competitive pressures in the storage sector. The current price sits near analyst consensus target of $170.73, suggesting limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
